Reduced action of insulin glargine on protein and lipid metabolism: Possible relationship to cellular hormone metabolism

Metabolism: Clinical and Experimental

Volumn 53, Issue 8, 2004, Pages 1037-1044

  Fawcett, Janet ^a,b   Tsui, Brian T ^a   Kruer, Michael C ^a   Duckworth, William C ^a,b,c  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; RECOMBINANT HUMAN INSULIN;

ARTICLE; CELL LABELING; CELL STRAIN 3T3; CELL STRAIN HEPG2; CONTROLLED STUDY; GLUCOSE METABOLISM; GLUCOSE OXIDATION; HORMONE BINDING; HORMONE METABOLISM; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; INSULIN DEGRADATION; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; MITOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS INHIBITION;

CELL MEMBRANE; CELLS, CULTURED; GLUCOSE; GLYCEROL; HORMONES; HUMANS; INSULIN; IODINE RADIOISOTOPES; ISOTOPE LABELING; LIPID METABOLISM; LIPIDS; LIPOLYSIS; OXIDATION-REDUCTION; PROTEINS; RECEPTOR, INSULIN; THYMIDINE;

EID: 3342972890     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.02.013     Document Type: Article

References (38)

1. Bolli G.B., Di Marchi R.D., Park G.D., et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 42:1999;1151-1167
2. Vajo Z., Duckworth W.C. Genetically engineered insulin analogs Diabetes in the new millenium. Pharmacol Rev. 52:2000;1-9
3. Brange J., Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev. 35:1999;307-335
4. Gillies P.S., Figgitt D.P., Lamb H.M. Insulin glargine. Drugs. 59:2000;253-260
5. Vajo Z., Fawcett J., Duckworth W.C. Recombinant DNA technology in the treatment of diabetes insulin analogs. Endocr Rev. 22:2001;706-717
6. Ciaraldi T.P., Carter L., Seipke G., et al. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells Comparisons to insulin and IGF-I. J Clin Endocrinol Metab. 86:2001;5838-5847
7. B32]insulin (HOE 901) in muscle cells. Eur J Pharmacol. 320:1997;259-265
8. Berti L., Kellerer M., Bossenmaier B., et al. The long acting human insulin analog HOE 901 Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res. 30:1998;123-129
9. Sandow J., Seipke G. In vitro pharmacology studies with insulin glargine and human insulin IGF-1 receptor binding and thymidine incorporation. Diabetes. 50:2001;A429. (abstr)
10. Kurtzhals P., Schäffer L., Sørensen A., et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 49:2000;999-1005
11. Kellerer M., Haring H.U. Insulin analogues Impact of cell model characteristics on results and conclusions regarding mitogenic properties. Exp Clin Endocrinol Diabetes. 109:2001;63-64
12. Umpleby A.M., Russell-Jones D.L. The hormonal control of protein metabolism. Baillieres Clin Endocrinol Metab. 10:1996;551-570
13. De Feo P. Hormonal regulation of human protein metabolism. Eur J Endocrinol. 135:1996;7-18
14. Duckworth W.C., Bennett R.G., Hamel F.G. Insulin degradation Progress and potential. Endocr Rev. 19:1998;608-624
15. B29 human insulin. Metabolism. 48:1999;611-617
16. Gunn J.M., Clark M.G., Knowles S.E., et al. Reduced rates of proteolysis in transformed cells. Nature. 266:1977;58-60
17. Fawcett J., Hamel F.G., Bennett R.G., et al. Insulin and analogue effects on protein degradation in different cell types. Dissociation between binding and activity. J Biol Chem. 276:2001;11552-11558
18. Chernick S.S. Determination of glycerol in acyl glycerols. Methods Enzymol. 14:1969;627-630
19. Levien T.L., Baker D.E., White J.R., et al. Insulin glargine A new basal insulin. Ann Pharmacother. 36:2002;1019-1027
20. Draznin B., Trowbridge M. Inhibition of intracellular proteolysis by insulin in isolated rat hepatocytes. Possible role of internalized hormone. J Biol Chem. 257:1982;11988-11993
21. Peavy D.E., Edmondson J.W., Duckworth W.C. Selective effects of inhibitors of hormone processing on insulin action in isolated hepatocytes. Endocrinology. 114:1984;753-760
22. Fawcett J., Hamel F.G., Duckworth W.C. Correlation of insulin inhibition of protein degradation to cellular insulin degradation comparing native insulin and insulin analogs. Diabetes. 50:2001;A275. (abstr)
23. Fawcett J., Hamel F.G., Duckworth W.C. Characterization of the inhibition of protein degradation by insulin in L6 cells. Arch Biochem Biophys. 385:2001;357-363
24. Hamel F.G., Bennett R.G., Upward J.L., et al. Insulin inhibits peroxisomal fatty acid oxidation in isolated rat hepatocytes. Endocrinology. 142:2001;2702-2706
25. Bennett R.G., Fawcett J., Kruer M.C., et al. Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme. J Endocrinol. 177:2003;399-405
26. Seipke G., Sandow J. Effects of insulin glargine, human insulin and the insulin analog Asp(B10) on the insulin receptor signaling cascade. Diabetes. 50:2001;A130-A131. (abstr)
27. Cheatham B., Kahn C.R. Insulin action and the insulin signaling network. Endocr Rev. 16:1995;117-142
28. Yamaguchi Y., Flier J.S., Yokota A., et al. Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology. 129:1981;2058-2066
29. Yamaguchi Y., Flier J.S., Benecke H., et al. Ligand-binding properties of the two isoforms of the human insulin receptor. Endocrinology. 132:1983;1132-1138
30. Seino S., Bell G.I. Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun. 159:1989;312-316
31. Kosaki A., Pillay T.S., Xu L., et al. The B isoform of the insulin receptor signals more efficiently that the A isoform in HepG2 cells. J Biol Chem. 270:1995;20816-20823
32. Kosaki A., Webster N.J. Effect of dexamethasone on the alternative splicing of the insulin receptor mRNA and insulin action in HepG2 hepatoma cells. J Biol Chem. 268:1993;21990-21996
33. Norgren S., Li L.-S., Luthman H. Regulation of human insulin receptor RNA splicing in HepG2 cells Effects of glucocorticoid and low glucose concentration. Biochem Biophys Res Commun. 199:1994;277-284
34. Reed B.C., Kaufmann S.H., Mackall J.C., et al. Alterations in insulin binding accompanying differentiation of 3T3-L1 preadipocytes. Proc Natl Acad Sci USA. 74:1977;4876-4880
35. Slieker L.J., Brooke G.S., Chance R.E., et al. Insulin and IGF-I analogs Novel approaches to improved insulin pharmacokinetics. LeRoith D., Raizada M.K. Current Directions in Insulin-Like Growth Factor Research. vol 343:1994;25-32 Plenum, New York, NY
36. Bornfeldt K.E., Gidlof R.A., Wasteson A., et al. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia. 34:1991;307-313
37. Hansen B.F., Danielsen G.M., Drejer K., et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J. 315:1996;271-279
38. Rosenstock J., Schwartz S.L., Clark C.M. Jr, et al. Basal insulin therapy in type 2 diabetes. 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 24:2001;631-636